Skip to main content
AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
7.38
+0.72 (10.81%)
At close: Jun 26, 2026, 4:00 PM EDT
7.39
+0.01 (0.14%)
After-hours: Jun 26, 2026, 7:58 PM EDT

AbCellera Biologics Operating Metrics

Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Programs Under Contract
- - - - - 739.00 710.00 692.00 679.00 660.00 642.00 633.00 607.00
Programs Under Contract Growth
- - - - - 11.97% 10.59% 9.32% 11.86% 16.20% 24.66% 39.43% 54.85%
Partnered Program Starts
- - - - - 404.00 392.00 374.00 356.00 339.00 342.00 319.00 291.00
Partnered Program Starts Growth
- - - - - 19.17% 14.62% 17.24% 22.34% 29.89% 45.53% 47.00% 41.95%
Number of Discovery Partners
- - - - - 170.00 164.00 160.00 157.00 152.00 148.00 145.00 140.00
Number of Discovery Partners Growth
- - - - - 11.84% 10.81% 10.34% 12.14% 14.29% 19.35% 26.09% 30.84%
Number of Molecules in the Clinic
60.00 57.00 54.00 50.00 45.00 41.00 36.00 33.00
Number of Molecules in the Clinic Growth
33.33% 39.02% 50.00% 51.52% 50.00% 51.85% 50.00% 50.00%

Revenue by Segment
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Research Fees
20.58M 26.28M 30.26M 30.38M 34.76M 35.56M 38.24M 39.33M
Research Fees Growth
-40.80% -26.08% -20.86% -22.75% -17.31% -12.86% 12.04% 23.89%
Milestone Payments
1.50M 1.50M 1.75M 1.75M 250.00K 1.50M 1.75M 2.15M
Milestone Payments Growth
500.00% - - -18.60% -88.37% 66.67% 337.50% -
Licensing
1.04M 1.05M 953.00K 921.00K 777.00K 969.00K 948.00K 916.00K
Licensing Growth
33.33% 8.26% 0.53% 0.55% -7.17% 39.22% 58.53% 44.48%
Royalty
- - - - - - 9.46M 102.78M
Royalty Growth
- - - - - - -98.34% -78.36%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.